


FIGURE 6 RESPONSE TO COVID-19 VACCINES VARIES IN PATIENTS WITH CANCER



Since the availability of COVID-19 vaccines, several studies have quantified the production of anti-SARS-CoV-2 antibodies as well as levels of immune cells in response to COVID-19 vaccines in patients with cancer. Findings of these studies suggest that most patients with solid tumors produce antibodies and mount cellular responses, depicted as an upward blue arrow in the left panel, that are similar to those without history of cancer. However, there

is a subset of patients with cancer who do not respond, or the strength of their response is weaker compared to that of healthy individuals (shown as a downward blue arrow in right panel). These patients include those who have hematologic malignancies, have received anticancer therapy that targets and depletes antibody-producing B cells (e.g., anti-CD20 antibody treatment or CAR T-cell therapy), or have received stem cell transplant.